These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26206053)

  • 1. [Duchenne muscular dystrophy].
    Meißner T
    MMW Fortschr Med; 2015 Jul; 157(13):81. PubMed ID: 26206053
    [No Abstract]   [Full Text] [Related]  

  • 2. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.
    Haas M; Vlcek V; Balabanov P; Salmonson T; Bakchine S; Markey G; Weise M; Schlosser-Weber G; Brohmann H; Yerro CP; Mendizabal MR; Stoyanova-Beninska V; Hillege HL
    Neuromuscul Disord; 2015 Jan; 25(1):5-13. PubMed ID: 25497400
    [No Abstract]   [Full Text] [Related]  

  • 3. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.
    Welch E; Goetz D; Almstead N
    Acta Myol; 2008 Oct; 27():63-8. PubMed ID: 19364064
    [No Abstract]   [Full Text] [Related]  

  • 4. PTC124, nonsense mutations and Duchenne muscular dystrophy.
    Wilton S
    Neuromuscul Disord; 2007 Oct; 17(9-10):719-20. PubMed ID: 17952895
    [No Abstract]   [Full Text] [Related]  

  • 5. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
    Finkel RS
    J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies point way to new therapeutic prospects for muscular dystrophy.
    Kuehn BM
    JAMA; 2007 Sep; 298(12):1385-6. PubMed ID: 17895449
    [No Abstract]   [Full Text] [Related]  

  • 7. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
    Campbell C; Barohn RJ; Bertini E; Chabrol B; Comi GP; Darras BT; Finkel RS; Flanigan KM; Goemans N; Iannaccone ST; Jones KJ; Kirschner J; Mah JK; Mathews KD; McDonald CM; Mercuri E; Nevo Y; Péréon Y; Renfroe JB; Ryan MM; Sampson JB; Schara U; Sejersen T; Selby K; Tulinius M; Vílchez JJ; Voit T; Wei LJ; Wong BL; Elfring G; Souza M; McIntosh J; Trifillis P; Peltz SW; Muntoni F; ; ;
    J Comp Eff Res; 2020 Oct; 9(14):973-984. PubMed ID: 32851872
    [No Abstract]   [Full Text] [Related]  

  • 8. A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy.
    Landfeldt E; Sejersen T; Tulinius M
    Acta Paediatr; 2019 Feb; 108(2):224-230. PubMed ID: 30188594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy.
    Landfeldt E; Lindberg C; Sejersen T
    Muscle Nerve; 2020 Mar; 61(3):363-368. PubMed ID: 31875971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoglycoside treatment for muscular dystrophy is scientifically rational, but is it clinically effective?
    Hirano M
    Curr Neurol Neurosci Rep; 2002 Jan; 2(1):53-4. PubMed ID: 11898583
    [No Abstract]   [Full Text] [Related]  

  • 11. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results.
    Politano L; Nigro G; Nigro V; Piluso G; Papparella S; Paciello O; Comi LI
    Acta Myol; 2003 May; 22(1):15-21. PubMed ID: 12966700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
    Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH
    Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the Editor.
    Scheuerbrandt G
    Acta Myol; 2015 May; 34(1):14. PubMed ID: 26155065
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
    Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
    Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataluren treatment of patients with nonsense mutation dystrophinopathy.
    Bushby K; Finkel R; Wong B; Barohn R; Campbell C; Comi GP; Connolly AM; Day JW; Flanigan KM; Goemans N; Jones KJ; Mercuri E; Quinlivan R; Renfroe JB; Russman B; Ryan MM; Tulinius M; Voit T; Moore SA; Lee Sweeney H; Abresch RT; Coleman KL; Eagle M; Florence J; Gappmaier E; Glanzman AM; Henricson E; Barth J; Elfring GL; Reha A; Spiegel RJ; O'donnell MW; Peltz SW; Mcdonald CM;
    Muscle Nerve; 2014 Oct; 50(4):477-87. PubMed ID: 25042182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry.
    Muntoni F; Desguerre I; Guglieri M; Osorio AN; Kirschner J; Tulinius M; Buccella F; Elfring G; Werner C; Schilling T; Trifillis P; Zhang O; Delage A; Santos CL; Mercuri E
    J Comp Eff Res; 2019 Oct; 8(14):1187-1200. PubMed ID: 31414621
    [No Abstract]   [Full Text] [Related]  

  • 17. The functional mechanisms and clinical application of read-through drugs.
    Fu Y; Shu ZY; Gu MM
    Yi Chuan; 2016 Jul; 38(7):623-633. PubMed ID: 27733335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy.
    Li D; McDonald CM; Elfring GL; Souza M; McIntosh J; Kim DH; Wei LJ
    JAMA Netw Open; 2020 Feb; 3(2):e1921306. PubMed ID: 32058550
    [No Abstract]   [Full Text] [Related]  

  • 20. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients.
    McDonald CM; Muntoni F; Penematsa V; Jiang J; Kristensen A; Bibbiani F; Goodwin E; Gordish-Dressman H; Morgenroth L; Werner C; Li J; Able R; Trifillis P; Tulinius M;
    J Comp Eff Res; 2022 Feb; 11(3):139-155. PubMed ID: 34791888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.